QGE031: Clinical Trials

15 trials of QGE031, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

8 completed, 5 terminated, 1 no longer available, 1 withdrawn. 10 Phase 2, 3 Phase 3, 2 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	10	Completed 6, Terminated 3, Withdrawn 1
Phase 3	3	Terminated 2, Completed 1
Phase 1	2	Completed 2

Follow QGE031: new trials by email Literature Review of QGE031 trials Research Report on QGE031

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines Ligelizumab, Placebo - Chronic Inducible Urticaria	Phase 3	Terminated	Novartis Pharmaceuticals	39	2021-11-16	2024-06-18
Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab Ligelizumab - Chronic Spontaneous Urticaria	Phase 3	Terminated	Novartis Pharmaceuticals	1033	2020-04-08	2024-06-20
A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines Ligelizumab - Chronic Spontaneous Urticaria	Phase 3	Completed	Novartis Pharmaceuticals	66	2019-04-13	2025-03-06
Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU) Ligelizumab, Placebo - Chronic Spontaneous Urticaria	Phase 2	Completed	Novartis Pharmaceuticals	49	2018-08-01	2026-01-13
A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients Ligelizumab - Chronic Spontaneous Urticaria	Phase 2	Completed	Novartis Pharmaceuticals	226	2016-05-24	2021-10-11
Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma QGE031, Placebo - Asthma	Phase 2	Terminated	Novartis Pharmaceuticals	10	2015-09-01	2017-08-11
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU QGE031, Omalizumab, Placebo - Chronic Spontaneous Urticaria	Phase 2	Completed	Novartis Pharmaceuticals	382	2015-07-15	2021-01-05
Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201 QGE031 - Asthma	Phase 2	Terminated	Novartis Pharmaceuticals	270	2014-03-27	2017-08-11
Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment QGE031, Placebo - Bullous Pemphigoid	Phase 2	Terminated	Novartis Pharmaceuticals	20	2013-01-01	2016-04-28
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma QGE031, Omalizumab, Placebo - Asthma	Phase 2	Completed	Novartis Pharmaceuticals	471	2012-12-01	2017-08-11
A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic Asthma QGE031, omalizumab, placebo - Allergic Asthma	Phase 1 / Phase 2	Completed	Novartis Pharmaceuticals	37	2012-11-01	2016-04-20
A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients QGE031, Placebo, Cyclosporine A - Atopic Dermatitis	Phase 2	Completed	Novartis Pharmaceuticals	22	2012-01-05	2017-02-23
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of QGE031 in Japanese Atopic Male Subjects QGE031, Placebo - Allergy	Phase 1	Completed	Novartis Pharmaceuticals	209	2011-03-01	2012-11-22
Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy QGE031, Placebo - Peanut Allergy	Phase 2	Withdrawn	Novartis Pharmaceuticals			2012-07-23
Global Managed Access Program Cohort for Ligelizumab in CSU Ligelizumab - Chronic Spontaneous Urticaria		No longer available	Novartis Pharmaceuticals			2022-05-11

Conditions studied

Sponsors

Countries

Results publications

NIH funding